Ability of fucoidan to prevent muscle necrosis induced by snake venom myotoxins: Comparison of high- and low-molecular weight fractions

Toxicon

Volumn 51, Issue 3, 2008, Pages 373-380

  Azofeifa, Karol ^a   Angulo, Yamileth ^a   Lomonte, Bruno ^a  

^a UNIVERSIDAD DE COSTA RICA   (Costa Rica)

Author keywords

Fucoidan; Myonecrosis; Myotoxin; Phospholipase A2; Venom

Indexed keywords

FUCOIDIN; SNAKE VENOM;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG INHIBITION; GEL FILTRATION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IN VIVO STUDY; MOUSE; MUSCLE NECROSIS; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; ANTICOAGULANTS; BOTHROPS; CROTALID VENOMS; MICE; MUSCULAR DISEASES; NECROSIS; PHOSPHOLIPASES A2; POLYSACCHARIDES;

BOTHROPS ASPER; SERPENTES;

EID: 39049169631     PISSN: 00410101     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.toxicon.2007.10.008     Document Type: Article

References (29)

1. 2 activity based on ligand-induced conformational change. J. Biol. Chem. 280 (2005) 7326-7335
2. 2. Biochem. Pharmacol. 66 (2003) 1993-2000
3. Chaves F., Loría G.D., Salazar A., and Gutiérrez J.M. Intramuscular administration of antivenoms in experimental envenomation by Bothrops asper: comparison between Fab and IgG. Toxicon 41 (2003) 237-244
4. 2. Biochem. J. 366 (2002) 971-976
5. Colliec C., Boisson-Vidal C., and Josefonvicz J. A low molecular fucoidan fraction from the brown seaweed Pelvetia canaliculata. Phytochemistry 35 (1994) 697-700
6. de Oliveira M., Cavalcante W.L., Arruda E.Z., Melo P.A., Dal-Pai Silva M., and Gallacci M. Antagonism of myotoxic and paralyzing activities of bothropstoxin-I by suramin. Toxicon 42 (2003) 373-379
7. 2 in the blood plasma of snakes. Toxicon 40 (2002) 481-484
8. Gutiérrez J.M., and Lomonte B. Efectos locales en el envenenamiento ofídico en América Latina. In: Costa Cardoso J.L., de Siqueira França F.O., Wen F.H., Sant'Ana Málaque C.M., and Haddad V. (Eds). Animais Peçonhentos no Brasil: biologia, clínica e terapêutica dos acidentes (2003), Sarvier Editora, São Paulo, Brasil 310-323
9. 2: insights into the mechanisms of local and systemic myotoxicity. Toxicon 42 (2003) 915-931
10. Gutiérrez J.M., León G., and Lomonte B. Pharmacokinetic-pharmacodynamic relationships of immunoglobulin therapy for envenomation. Clin. Pharmacokinet. 42 (2003) 721-741
11. Gutiérrez J.M., Theakston R.D.G., and Warrell D.A. Confronting the neglected problem of snake bite envenoming: the need for a global partnership. PLoS Med. 3 (2006) e150 10.1371/journal.pmed.0030150
12. 2 fragments of horse antivenom in the treatment of local symptoms after Cerastes cerastes (Egyptian snake) bite. Afr. J. Biotechnol. 2 (2003) 189-193
13. 2 polyvalent antivenoms do not differ in their ability to neutralize hemorrhage, edema and myonecrosis induced by Bothrops asper (terciopelo) snake venom. Toxicon 35 (1997) 1627-1633
14. León G., Valverde J.M., Rojas G., Lomonte B., and Gutiérrez J.M. Comparative study on the ability of IgG and Fab sheep antivenoms to neutralize local hemorrhage, edema, and myonecrosis induced by Bothrops asper (terciopelo) snake venom. Toxicon 38 (2000) 233-244
15. 2 myotoxin inhibitor proteins from snakes, mammals and plants. Toxicon 42 (2003) 963-977
16. Lomonte B., and Gutiérrez J.M. A new muscle damaging toxin, myotoxin II, from the venom of the snake Bothrops asper (terciopelo). Toxicon 27 (1989) 725-733
17. Lomonte B., Gutiérrez J.M., Rojas G., and Calderón L. Quantitation by enzyme-immunoassay of antibodies against Bothrops myotoxins in four commercially-available antivenoms. Toxicon 29 (1991) 695-702
18. 2 from Bothrops asper snake venom by glycosaminoglycans of the heparin/heparan sulfate family. Biochem. Pharmacol. 47 (1994) 1509-1518
19. 2 from Bothrops asper snake venom. Identification of a heparin-binding and cytolytic toxin region by the use of synthetic peptides and molecular modeling. J. Biol. Chem. 269 (1994) 29867-29873
20. 2 myotoxins from crotalid snake venoms and their structural determinants of myotoxic action. Toxicon 42 (2003) 885-901
21. Melo P.A., and Suarez-Kurtz G. Release of sarcoplasmic enzymes from skeletal muscle by Bothrops jararacussu venom: antagonism by heparin and by the serum of South American marsupials. Toxicon 26 (1988) 87-95
22. Murakami M.T., Arruda E.Z., Melo P.A., Martinez A.B., Lomonte B., Gutiérrez J.M., and Arni R.K. Inhibition of myotoxic activity of Bothrops asper myotoxin II by the anti-trypanosomal drug suramin. J. Mol. Biol. 350 (2005) 416-426
23. 2 from Agkistrodon piscivorus piscivorus snake venom: synthetic C-terminal peptides from Lys49, but not from Asp49 myotoxins, exert membrane-damaging activities. Toxicon 39 (2001) 1587-1594
24. Ownby C.L., Odell G.V., and Theakston R.D.G. Detection of antibodies to myotoxin a and prairie rattlesnake (Crotalus viridis viridis) venom in three antisera using enzyme-linked immunosorbent assay and immunodiffusion. Toxicon 21 (1983) 849-855
25. Patankar M., Oehninger S., Barnett T., Williams R., and Clark G. A revised structure for fucoidan may explain some of its biological activities. J. Biol. Chem. 268 (1993) 21770-21776
26. Rucavado A., and Lomonte B. Neutralization of myonecrosis, hemorrhage, and edema induced by Bothrops asper snake venom by homologous and heterologous pre-existing antibodies in mice. Toxicon 34 (1996) 567-577
27. Soares A.M., Ticli F.K., Marcussi S., Lourenço M.V., Januário A.H., Sampaio S.V., Giglio J.R., Lomonte B., and Pereira P.S. Medicinal plants with inhibitory properties against snake venoms. Curr. Med. Chem. 12 (2005) 2625-2641
28. Tissot B., Gonnet F., Iborra A., Berthou C., Thielens N., Arlaud G., and Daniel R. Mass spectrometry analysis of the oligomeric C1q protein reveals the B chain as the target of trypsin cleavage and interaction with fucoidan. Biochemistry 44 (2005) 2602-2609
29. Warrell D.A. Clinical features of envenoming from snake bites. In: Bon C., and Goyffon M. (Eds). Envenomings and their Treatments (1996), Fondation Marcel Mérieux, Lyon 63-76